Silverberg Bernstein Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$653K Sell
22,883
-400
-2% -$10.6K 0.31% 43
2026
Q2
$561K Buy
23,283
+167
+0.7% +$4.37K 0.21% 46
2026
Q1
$649K Sell
23,116
-734
-3% -$19.5K 0.36% 45
2025
Q4
$594K Buy
23,850
+2,500
+12% +$63K 0.34% 45
2025
Q3
$544K Buy
21,350
+7,500
+54% +$185K 0.33% 46
2025
Q2
$336K Buy
13,850
+4,050
+41% +$94.4K 0.23% 52
2025
Q1
$248K Buy
9,800
+1,600
+20% +$41.9K 0.23% 51
2024
Q4
$218K Sell
8,200
-500
-6% -$13.6K 0.19% 46
2024
Q3
$252K Buy
+8,700
New +$254K 0.23% 46

Other funds holding PFE

Silverberg Bernstein Capital Management's PFE Position: Q3 2026 in Review

Silverberg Bernstein Capital Management reduced its Pfizer (PFE) stake by 1.7% in Q3 2026, selling an estimated $10.6K and leaving 22,883 shares worth $653K. The position accounts for 0.31% of the portfolio, ranked #43.

Silverberg Bernstein Capital Management first reported a position in PFE in Q3 2024 and has held it in 9 quarters since. 2,920 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Silverberg Bernstein Capital Management held 22,883 shares of Pfizer worth $653K as of Q3 2026.
  • Silverberg Bernstein Capital Management sold 400 Pfizer shares in Q3 2026, an estimated $10.6K.
  • Pfizer made up 0.31% of Silverberg Bernstein Capital Management's portfolio in Q3 2026, its #43 holding.
  • Silverberg Bernstein Capital Management first reported a position in Pfizer in Q3 2024 and has held it in 9 quarters since.
  • 2,920 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Silverberg Bernstein Capital Management's 13F filing for Q3 2026, filed 13 Oct 2026.